Generic Lovenox shows US/EU split on data requirements
This article was originally published in Scrip
Executive Summary
The US approval of Sandoz' generic version of Sanofi-Aventis' antithrombotic Lovenox (enoxaparin sodium) raises a number of questions, not least why the FDA sees the product as a generic while for the European authorities a low molecular weight heparin (LMWH) is a biosimilar drug requiring clinical trials for approval.